Sigma Planning Corp Increases Stake in iShares Biotechnology ETF $IBB

Sigma Planning Corp boosted its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 60.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,031 shares of the financial services provider’s stock after buying an additional 3,766 shares during the quarter. Sigma Planning Corp’s holdings in iShares Biotechnology ETF were worth $1,694,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Valmark Advisers Inc. increased its position in shares of iShares Biotechnology ETF by 3.2% during the first quarter. Valmark Advisers Inc. now owns 2,435 shares of the financial services provider’s stock worth $411,000 after acquiring an additional 75 shares during the period. Midwest Trust Co boosted its holdings in iShares Biotechnology ETF by 37.8% in the first quarter. Midwest Trust Co now owns 4,894 shares of the financial services provider’s stock valued at $826,000 after purchasing an additional 1,343 shares during the period. Fifth Third Bancorp boosted its holdings in iShares Biotechnology ETF by 106.4% in the first quarter. Fifth Third Bancorp now owns 27,352 shares of the financial services provider’s stock valued at $4,618,000 after purchasing an additional 14,097 shares during the period. Sovran Advisors LLC grew its stake in iShares Biotechnology ETF by 18.9% during the 1st quarter. Sovran Advisors LLC now owns 1,490 shares of the financial services provider’s stock worth $251,000 after purchasing an additional 237 shares in the last quarter. Finally, Simplicity Wealth LLC grew its stake in iShares Biotechnology ETF by 10.3% during the 1st quarter. Simplicity Wealth LLC now owns 4,666 shares of the financial services provider’s stock worth $788,000 after purchasing an additional 434 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $189.76 on Friday. The stock’s 50-day moving average is $177.79 and its two-hundred day moving average is $173.40. iShares Biotechnology ETF has a 1-year low of $128.84 and a 1-year high of $199.05.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were paid a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.1%. The ex-dividend date was Monday, June 15th.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.